Keloid
Conditions
Brief summary
The paucity of local literature regarding the comparison of intralesional verapamil with intralesional triamcinolone acetonide led this study to be carried out with the objective of comparing the clinical effectiveness of intralesional triamcinolone acetonide and intralesional verapamil hydrochloride in patients with keloids.
Detailed description
Although the anti-inflammatory and scar-enhancing properties of corticosteroids on hypertrophic scars and keloids have been investigated and documented thoroughly. There are many different treatments for keloids nowadays; each method has its advantages and disadvantages, and the results also vary depending on each study. Moreover, local data to address this issue is also scarce. The findings of this study would not add to the existing stats, but comparing the outcomes of both the drugs would also guide clinicians towards better management of keloids by choosing the more appropriate treatment.
Interventions
DRUGTriamcinolone Acetonide
Patients received intralesional triamcinolone acetonide (20 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.
Patients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.
Sponsors
Muhammad Aamir Latif
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Either gender * Aged between 20 and 60 years * With keloids * Benign dermal growths * Scar length not exceeding 5 centimeters * Keloid duration of five years or less * A baseline Vancouver Scar Scale score of 5 or more
Exclusion criteria
* Pregnant or lactating women * A family history of keloids * Diagnosed with conditions such as acromegaly, diabetes mellitus, or congestive cardiac disease * a history of thyroidectomy * Current or recent use of isotretinoin or anabolic steroids, as determined by history, physical examination, blood glucose analysis, and electrocardiography
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Scar assessment | 24 weeks | Using the Vancouver Scar Scale, height, vascularity, pliability, and pigmentation were assessed at baseline and compared with post-treatment measures at 24 weeks. A score closer to 0 was deemed as better vascularity (not red), low pigmentation, high pliability (soft), and low thickness. |
Countries
Pakistan
Contacts
PRINCIPAL_INVESTIGATORBakhtawar
Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur
STUDY_DIRECTORSalman Ashraf, FCPS
Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur
Outcome results
None listed